Truist raised the firm’s price target on Hims & Hers to $48 from $45 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as “relatively selective”, the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- With Hims & Hers Health Stock (HIMS) Up 108%, Let’s Look at Who Owns It
- Mixed options sentiment in Hims and Hers Health with shares up 2.49%
- Hims & Hers (HIMS) Faces Legal Storm Post Novo Nordisk Breakup
- Is Hims & Hers (HIMS) Stock a Buy After the Recent Pullback? Here’s What Analysts Say
- Hims & Hers app downloads negative y/y in June, says Morgan Stanley